Matthias Piesche

Departamento de Ciencias Preclínicas. Laboratorio de Investigaciones Biomédicas, Facultad de Medicina UCM

Línea de investigación: Inmunoterapia para el cáncer: Utilizando bioingeniería para reprogramar macrófagos M2 inmunosupresores en macrófagos M1 tumoricidas para generar una fuerte inmunidad antitumoral. Nuestro enfoque también proporciona una terapia específica para el paciente dirigida a todas las mutaciones del tumor del paciente (“neoantígenos”). Biomarcador del cáncer: Desarrollo de un biomarcador no invasivo (biopsia líquida) para detectar cáncer gástrico en etapas tempranas y en recurrencia.

Grado académico:

• Master en Biología, Universidad Bonn, ALemania, 2002
• Ph.D. en  inmunoterapía contra cáncer, Universidad Goettingen, Alemania, 2006

Publicaciones y Artículos:

• Patente #18/134,636, Prevención y tratamiento de Covid mediante un inhibidor de integrinas (2023) 
• Huntington KE, Carlsen L, So EY, Piesche M, Liang O, El-Deiry W. "Integrin/TGF-Beta1 inhibitor GLPG-0187 blocks SARS-CoV-2 Delta and Omicron pseudovirus infection of airway epithelial cells which could attenuate disease severity." Pharmaceuticals. 2022 May 17;15(5):618. PMID: 35631444 * Corresponding author
• Carvacho I and Piesche M. “RGD-binding integrins and TGF-b in SARS-CoV-2 infections – novel targets to treat COVID-19 patients?” Clin Transl Immunology. 2021 Mar 18;10(3):e1240, PMID: 33747508,   Corresponding author
• Herrada AA, Olate-Briones A, Rojas A, Liu C, Escobedo N, Piesche M. ” Adipose tissue macrophages as a therapeutic target in obesity-associated diseases.” Obes Rev. 2021 Jun;22(6):e13200. PMID: 33426811, * Corresponding authors
• Piesche M, Roos J, Kühn B, et al. ”The emerging therapeutic potential of nitro fatty acids and other Michael acceptor-containing drugs for the treatment of inflammation and cancer.” Front  Pharmacol. 2020 Sep 3;11:1297, PMID: 33013366, * Corresponding authors
• Piesche M, et al. “Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions.” Clin Cancer Res. 2015 Mar 1; 21(5):1010-8, PMID: 25538258
• Solorza J, Oliva CA, Castillo K, Amestica G, Lopez X, Maldifassi MC, Barra RA, Stehberg J, Piesche M, et al. ”Effects of Interleukin-1β in glycinergic transmission in the Central amygdala”. Front Pharmacol. 2021 Mar 5;12:613105, PMID: 33746753
• Carvacho I, Piesche M, Maier TJ, Machaca K. Ion channel function during oocyte maturation and fertilization. Front Cell Dev Biol. 2018 Jun 26;6:63, PMID: 29998105
• Roos J, Peters M, Maucher I, Kühn B, Fettel J, Urbschat A, Piesche M, et al. Drug-mediated intracellular donation of nitric oxide potently inhibits 5-lipoxygenase: a possible key to future anti-leukotriene therapy. Antioxid Redox Signal. 2018 May 10;28(14):1265-1285, PMID: 28699354
• Ho V; Kim H; Bavli N; Mihm M; Pozdnyakova O, Piesche M, et al. “Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT.” Blood Adv. 2017 Nov 14;1(24):2269-2279, PMID: 29296875
• Zhou J, Mahoney KM, Giobbie-Hurder A, Zhao F, Lee S, Liao X, Rodig S, Li J, Wu X, Butterfield L, Piesche M, et al. “Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade.” Cancer Immunol Res. 2017 Jun; 5(6):480-492, PMID: 28522460
• Wu X, Li J, Connolly EM, Liao X, Ouyang J, Giobbie-Hurder A, Lawrence D, McDermott D, Murphy G,  Zhou J, Piesche M, et al. ”Combined anti-VEGF and anti-CTLA-4 therapy elicits humoral immunity to galectin-1 which is associated with favorable clinical outcomes.” Cancer Immunol Res. 2017 Jun; 5(6):446-454, PMID 28473314
• Maucher IV, Rühl M, Kretschmer SB, Hofmann B, Kühn B, Fettel J, Vogel A, Flügel KT, Manolikakes G, Hellmuth N, Häfner AK, Golghalyani V, Ball AK, Piesche M, et al. ”Michael acceptor containing drugs are a novel class of 5-lipoxygenase inhibitor targeting the surface cysteines C416 and C418.” Biochem Pharmacol. 2017 Feb 1;125:55-74, PMID 27823964
• Curry WT, Gorrepati R, Piesche M, et al. “Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Anti-tumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.” Clin Cancer Res. 2016 Jun 15; 22(12): 2885-96, PMID 26873960
• Roos J, Grösch S, Werz O, Schröder P, Ziegler S, Fulda S, Paulus P, Urbschat A, Kühn B, Maucher I, Fettel J, Vorup-Jensen Th, Piesche M, et al. “Regulation of tumorigenic Wnt signaling by cyclooxygenase-2,5-lipoxygenase and their pharmacological inhibitors: a basis for novel drugs targeting cancer cells? Pharmacol Ther.” 2016 Jan; 157:43-64, PMID 26549540
• Huntington KE, Carlsen L, So EY, Piesche M, Liang O, El-Deiry W. “Integrin/TGF-Beta1 inhibitor GLPG-0187 blocks SARS-CoV-2 Delta and Omicron pseudovirus infection of airway epithelial cells which could attenuate disease severity.” Pharmaceuticals. 2022 May 17;15(5):618. PMID: 35631444 * Corresponding author
• Carvacho I and Piesche M. “RGD-binding integrins and TGF-b in SARS-CoV-2 infections – novel targets to treat COVID-19 patients?” Clin Transl Immunology. 2021 Mar 18;10(3):e1240, PMID: 33747508,   Corresponding author
• Herrada AA, Olate-Briones A, Rojas A, Liu C, Escobedo N, Piesche M. ” Adipose tissue macrophages as a therapeutic target in obesity-associated diseases.” Obes Rev. 2021 Jun;22(6):e13200. PMID: 33426811, * Corresponding authors
• Piesche M, Roos J, Kühn B, et al. ”The emerging therapeutic potential of nitro fatty acids and other Michael acceptor-containing drugs for the treatment of inflammation and cancer.” Front  Pharmacol. 2020 Sep 3;11:1297, PMID: 33013366, * Corresponding authors
• Piesche M, et al. “Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions.” Clin Cancer Res. 2015 Mar 1; 21(5):1010-8, PMID: 25538258